In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acceleron Pharma, Inc.

Latest From Acceleron Pharma, Inc.

With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy

The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.

Approvals Launches

Marching On: Eight Novel Agents Among March Goal Dates For US FDA

Crowded calendar could bring to an end the slow start for novel approvals in 2024, as decisions come due for Lilly’s donanemab, Merck’s sotatercept, Regeneron’s odronextamab and more.

US FDA Performance Tracker Approvals

Merck & Co. Heads Into A Year Of Portfolio Expansion

The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.

Sales & Earnings Launches

How To Improve Reporting? Have Centralized Unit Oversee Tasks

Report by Clinical Trials Transformation Initiative identifies barriers to registration and reporting of clinical trial results to and the need for centralized approach to monitor process and educate those responsible for submitting information to the site.

Clinical Trials FDA
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule